Retatrutide ReportClinical & Regulatory Intelligence

Independent Clinical & Regulatory Intelligence

Retatrutide Report

Clinical trials, research, efficacy, safety and regulatory developments — tracked in one place.

Independent research platform. Not affiliated with Eli Lilly and Company.

View Clinical TrialsTrack FDA Progress

Compound Status

Database record
Compound
LY3437943
Stage
Phase 3
FDA Approved
No
Status
Investigational
Developer
Eli Lilly and Company
Next Milestone
Company plans BLA submission in Q1 2027 (company-planned, not yet filed; not FDA approved)

Last verified: 18 Oct 2026

Primary source: Eli Lilly and Company

  • Development stage

    Verified

    Phase 3

    Database record · 4 Sept 2026

  • Retatrutide intervention trials

    Verified

    34

    Database record · 2 Nov 2026

  • Latest verified clinical results

    Verified
    Weight loss
    -20.8%

    TRIUMPH-2 · 12 mg · 80 wk · Efficacy estimand · Lilly source

    A1C
    -1.5 percentage points

    TRIUMPH-2 · 12 mg · 80 wk · Efficacy estimand · Lilly source

    Database record · 2 Nov 2026

  • Expected Regulatory Filing

    Unverified

    Company plans BLA submission in Q1 2027 (company-planned, not yet filed; not FDA approved)

    Database record · Not yet confirmed

Efficacy

Latest Verified Phase 3 Result

TRIUMPH-2 · NCT05929079

-20.8%

Mean change in body weight

Retatrutide 12 mg · 80 weeks · Adults with type 2 diabetes and obesity or overweight · Efficacy estimand

Peer-reviewed Phase 3
What this means

A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.

Figure / record sourceLast verified 30 Sept 2026

Peer-reviewed publicationLast verified 13 Oct 2026

All verified results →

Within one trial

Reported results, in view

  • Retatrutide 4 mg-1.4 percentage points
    4 mg: -1.4 percentage points
  • Retatrutide 9 mg-1.6 percentage points
    9 mg: -1.6 percentage points
  • Retatrutide 12 mg-1.5 percentage points
    12 mg: -1.5 percentage points
  • Placebo-0.2 percentage points
    Placebo: -0.2 percentage points
← Decrease from baselineZero baseline

Reported change from baseline; zero means no change. Study arms are shown as reported, not as a placebo-adjusted difference. No uncertainty intervals are supplied by these structured records.

NCT05929079 · 80 weeks

TRIUMPH-2

Adults with type 2 diabetes and obesity or overweight

Efficacy estimand

Source published 23 Jul 2026

Peer-reviewed Phase 3
What this means

A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.

Figure / record sourceLast verified 30 Sept 2026

Peer-reviewed publicationLast verified 13 Oct 2026

How to read this result
Population
Adults with type 2 diabetes and obesity or overweight
Endpoint
Change in A1C from baseline
Reported timepoint
80 weeks
Study arm
4 mg
Analysis / estimand
Efficacy estimand

An estimand defines the treatment effect a trial aims to estimate, including how treatment discontinuation or other events are handled. The analysis label above is reproduced from the verified record; methods should be checked in its source.

Study-arm labels describe the research, not dosing advice. Efficacy does not establish safety, and cross-trial comparisons are not head-to-head comparisons.

Figure source: Eli Lilly — TRIUMPH-2 and TRIUMPH-3 topline results (23 Jul 2026)Published 23 Jul 2026 · Verified 30 Sept 2026

Trial design and endpointsVerified safety evidence
Trial record →

Cross-trial comparisons are not head-to-head comparisons. Each chart has its own scale; populations, durations and methods differ. Study-arm labels are not dosing advice. Read safety evidence separately.

Evidence briefing

What we know. What remains unknown.

Confirmed in these records

Current confirmed FDA-tracker stage: Phase 3 programme

Supporting record · Verified 2 Nov 2026

Full regulatory status and freshness

  • TRIUMPH-2: Peer-reviewed Phase 3

    Verified efficacy records available. Numerical provenance remains the linked figure source.

    Figure source · Verified 30 Sept 2026

    Linked peer-reviewed publication · Verified 13 Oct 2026

  • TRIUMPH-3: Sponsor topline result

    Verified efficacy records available. Numerical provenance remains the linked figure source.

    Figure source · Verified 30 Sept 2026

  • TRIUMPH-1: Peer-reviewed Phase 3

    Verified efficacy records available. Numerical provenance remains the linked figure source.

    Figure source · Verified 30 Sept 2026

    Linked peer-reviewed publication · Verified 13 Oct 2026

  • TRANSCEND-T2D-1: Peer-reviewed Phase 3

    Verified efficacy records available. Numerical provenance remains the linked figure source.

    Figure source · Verified 30 Sept 2026

    Linked peer-reviewed publication · Verified 13 Oct 2026

  • TRIUMPH-4: Sponsor topline result

    Verified efficacy records available. Numerical provenance remains the linked figure source.

    Figure source · Verified 30 Sept 2026

Not established by this view

  • A head-to-head ranking.

    Separate trial results do not establish which treatment or trial performed better. Populations, endpoints and methods differ.

    Reported results and study context
  • Precision beyond the recorded values.

    The structured efficacy records do not provide confidence intervals or arm-level sample sizes. Check the linked original source; missing fields here do not mean the source omitted them.

  • An individual treatment response or safety conclusion.

    Trial-level efficacy is not a prediction for a person, and missing safety records are not evidence of no adverse events.

    Separate verified safety evidence and limitations
  • An FDA-specific monitoring timestamp.

    This view does not supply when FDA sources were last checked. Record verification dates and the site’s overall sync time are different.

    Tracker verification and monitoring labels

“Unknown” here describes the limits of these stored records—not proof that evidence does not exist. Source verification is not medical review.

Developments

Latest Retatrutide Developments

Verified FDA, EMA and Eli Lilly source documents, newly indexed peer-reviewed research and approved editorial analysis. Every entry links to its source record.

View all developments
Research update

Diabetes, obesity & metabolism

Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.

AIMS: To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). MATERIALS AND METHODS: Data were analysed from two randomised, double-blind, placebo-controlled phase 2 trials.

1 Nov 2026

Indexed from PubMed

Source
Research update

Journal of chromatography. A

Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.

Source summary

Not yet confirmed

11 Oct 2026

Indexed from PubMed

Source
Research update

Lancet (London, England)

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Source summary

BACKGROUND: Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea. We aimed to assess the efficacy and safety of retatrutide in adults with obesity and type 2 diabetes.

10 Oct 2026

Indexed from PubMed

Source
Official source updatemedium

Eli Lilly and Company

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes

Source summary

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity Participants with a baseline BMI of 35 or higher who took retatrutide 12 mg lost up to an

29 Sept 2026

Confirmed against source document

Source

Mechanism

Why is retatrutide different?

See How Retatrutide Works →

Simplified receptor-level overview

Investigational — not FDA approved

Retatrutide and its three receptor targetsOne investigational molecule branches to GLP-1, GIP and glucagon receptors. Lines rejoin beside outcomes studied in clinical trials, without implying guaranteed outcomes.

Retatrutide

LY3437943

single investigational molecule

Clinical assessment

Outcomes measured in clinical trials

  • Body weight
  • A1C
  • Safety/tolerability

A closer look · cell signalling

From the cell surface to a signal inside

Pancreatic β cell · schematicGLP-1R
GLP-1 receptor: Receptor bindingA simplified cell cross-section. Retatrutide binds outside the cell to a membrane receptor; a signal is relayed inside towards a tissue-dependent cellular response. The nucleus is shown for orientation only.Outside the cellRetatrutideCell membraneInside the cellNucleuscAMP signalling

Receptor binding

Retatrutide binds to a receptor on the cell surface. Receptor expression differs between tissues.

GLP-1 receptor context. GLP-1 receptor signalling can support glucose-dependent insulin secretion. Appetite-related effects also involve other tissues and neural pathways.

Simplified receptor biology, not microscopy or a prediction of treatment response. These receptor views represent different tissue contexts—not three receptors necessarily present on the same cell. Timing and scale are illustrative; the diagram does not show fat cells shrinking or establish clinical benefit.

Retatrutide discovery and receptor pharmacology ↗
The diagram shows receptor targets and studied biological pathways, not guaranteed individual outcomes.

Weekly Briefing

The Retatrutide Report

The most important retatrutide developments, once a week.

  • Clinical trial changes
  • New PubMed research
  • FDA / EMA regulatory developments
  • Eli Lilly announcements
  • Major efficacy and safety updates

No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.

Status Dashboard

Retatrutide development status

A consolidated view of the compound's development stage, regulatory standing and next expected milestone.

Development Timeline

Last verified: 18 Oct 2026

  1. ✓

    Discovery

    Complete

  2. ✓

    Phase 1

    Complete

  3. ✓

    Phase 2

    Complete

  4. Phase 3

    Current

  5. FDA Submission

    Pending

  6. FDA Review

    Pending

  7. Approval

    Pending

Current stage

Phase 3

Next milestone

Company plans BLA submission in Q1 2027 (company-planned, not yet filed; not FDA approved)

Expected timing

Company plans BLA submission in Q1 2027 (company-planned, not yet filed; not FDA approved)

Last development

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes

Last verified

18 Oct 2026

Source

Eli Lilly and Company

Compound Record

Developer
Eli Lilly and Company
Compound
Retatrutide
Compound code
LY3437943
Mechanism
GLP-1 / GIP / Glucagon receptor agonist
Development Stage
Phase 3
FDA Approved
No
Regulatory Status
Investigational
Next Expected Milestone
Company plans BLA submission in Q1 2027 (company-planned, not yet filed; not FDA approved)
Primary Source
Eli Lilly and Company
Latest Source Check
18 Oct 2026
Last Updated
4 Sept 2026

What Changed

What changed in the record

Counts of source-detected changes stored in the database. Every figure comes from a recorded registry, literature or regulatory event.

View Change History

Today

Clinical trial changes
0
New publications
0
Regulatory developments
0

Last 7 days

Clinical trial changes
0
New publications
0
Regulatory developments
0

Trial Registry

Retatrutide Clinical Trial Tracker

Registered studies across obesity, type 2 diabetes and related indications, with status and completion timing.

View All Clinical Trials

  • TRIUMPH-5

    ID
    NCT06662383
    Phase
    Phase 3
    Status
    Active, not recruiting
    Primary completion
    1 Nov 2026
    Indication
    Obesity

  • TRIUMPH-8

    ID
    NCT07232719
    Phase
    Phase 3
    Status
    Active, not recruiting
    Primary completion
    1 Jul 2027
    Indication
    Obesity, Overweight

  • TRIUMPH-7

    ID
    NCT07035093
    Phase
    Phase 3
    Status
    Active, not recruiting
    Primary completion
    1 Sept 2027
    Indication
    Obesity, Overweight, Chronic Low Back Pain (CLBP)

  • TRIUMPH-6

    ID
    NCT06859268
    Phase
    Phase 3
    Status
    Active, not recruiting
    Primary completion
    1 Apr 2028
    Indication
    Obesity

  • TRIUMPH-9

    ID
    NCT07357415
    Phase
    Phase 3
    Status
    Active, not recruiting
    Primary completion
    1 Oct 2028
    Indication
    Obesity, Overweight

  • TRIUMPH-2

    ID
    NCT05929079
    Phase
    Phase 3
    Status
    Completed
    Primary completion
    16 Jun 2026
    Indication
    Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea

View all clinical trials →

Records are shown exactly as stored in the Retatrutide Report database. A record is marked verified only once a source and a verification timestamp have been recorded.

Regulatory

Retatrutide FDA Approval Tracker

The verified Phase 3 programme is based on trial registry records. United States regulatory milestones advance only when an official record is source-verified and approved for public status; pending developments do not advance the confirmed stage.

  1. ✓

    Phase 3 programme

    14 verified Phase 3 registry records

  2. FDA submission

    Not confirmed by an official source

  3. Filing acceptance

    Not confirmed by an official source

  4. FDA review

    Not confirmed by an official source

  5. FDA decision

    Not confirmed by an official source

  6. Commercial launch

    Not confirmed by an official source

Record verification is separate from monitoring freshness. The site sync time covers multiple sources and does not prove that FDA sources were checked at that time.

Current confirmed stage
Phase 3 programme
Latest official development
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Development date
29 Sept 2026
Source
Eli Lilly and Company ↗
Latest approved record verified
18 Oct 2026 16:00 UTC
FDA sources last checked
FDA-specific check time not available in this view
Site sources last synced
2 Nov 2026 17:15 UTC
Approval status
No FDA approval confirmed in verified records

Company-planned milestone

Lilly plans to submit a biologics license application (BLA) in Q1 2027. The application has not yet been filed, and this is not an approval date. Source: Eli Lilly announcement

Results Explorer

Verified Phase 3 Results

A preview of verified efficacy endpoints. Filter every verified value by trial, dose, endpoint and duration in the full explorer.

Results from different trials should not be compared directly because populations, study designs, treatment durations, endpoints and analysis methods may differ.

  • TRIUMPH-2 · 12 mg

    -20.8%

    Mean change in body weight

    80 weeks · Efficacy estimand

    Peer-reviewed Phase 3
    What this means

    A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.

    Figure / record sourceLast verified 30 Sept 2026

    Peer-reviewed publicationLast verified 13 Oct 2026

    How to read this result
    Population
    Adults with type 2 diabetes and obesity or overweight
    Endpoint
    Mean change in body weight
    Reported timepoint
    80 weeks
    Study arm
    12 mg
    Analysis / estimand
    Efficacy estimand

    An estimand defines the treatment effect a trial aims to estimate, including how treatment discontinuation or other events are handled. The analysis label above is reproduced from the verified record; methods should be checked in its source.

    Study-arm labels describe the research, not dosing advice. Efficacy does not establish safety, and cross-trial comparisons are not head-to-head comparisons.

    Figure source: Eli Lilly — TRIUMPH-2 and TRIUMPH-3 topline results (23 Jul 2026)Published 23 Jul 2026 · Verified 30 Sept 2026

    Trial design and endpointsVerified safety evidence

  • TRIUMPH-3 · 12 mg

    -22.6%

    Mean change in body weight

    80 weeks · Efficacy estimand

    Sponsor topline result
    What this means

    The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.

    Figure / record sourceLast verified 30 Sept 2026

    How to read this result
    Population
    Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes
    Endpoint
    Mean change in body weight
    Reported timepoint
    80 weeks
    Study arm
    12 mg
    Analysis / estimand
    Efficacy estimand

    An estimand defines the treatment effect a trial aims to estimate, including how treatment discontinuation or other events are handled. The analysis label above is reproduced from the verified record; methods should be checked in its source.

    Study-arm labels describe the research, not dosing advice. Efficacy does not establish safety, and cross-trial comparisons are not head-to-head comparisons.

    Figure source: Eli Lilly — TRIUMPH-2 and TRIUMPH-3 topline results (23 Jul 2026)Published 23 Jul 2026 · Verified 30 Sept 2026

    Trial design and endpointsVerified safety evidence

  • TRIUMPH-1 · 12 mg

    -28.3%

    Mean change in body weight

    80 weeks · Efficacy estimand

    Peer-reviewed Phase 3
    What this means

    A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.

    Figure / record sourceLast verified 30 Sept 2026

    Peer-reviewed publicationLast verified 13 Oct 2026

    How to read this result
    Population
    Adults with obesity or overweight without diabetes
    Endpoint
    Mean change in body weight
    Reported timepoint
    80 weeks
    Study arm
    12 mg
    Analysis / estimand
    Efficacy estimand

    An estimand defines the treatment effect a trial aims to estimate, including how treatment discontinuation or other events are handled. The analysis label above is reproduced from the verified record; methods should be checked in its source.

    Study-arm labels describe the research, not dosing advice. Efficacy does not establish safety, and cross-trial comparisons are not head-to-head comparisons.

    Figure source: Eli Lilly — TRIUMPH-1 topline results (21 May 2026)Published 21 May 2026 · Verified 30 Sept 2026

    Trial design and endpointsVerified safety evidence

  • TRANSCEND-T2D-1 · 12 mg

    -16.8%

    Mean change in body weight

    40 weeks · Efficacy estimand

    Peer-reviewed Phase 3
    What this means

    A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.

    Figure / record sourceLast verified 30 Sept 2026

    Peer-reviewed publicationLast verified 13 Oct 2026

    How to read this result
    Population
    Adults with type 2 diabetes inadequately controlled by diet and exercise alone
    Endpoint
    Mean change in body weight
    Reported timepoint
    40 weeks
    Study arm
    12 mg
    Analysis / estimand
    Efficacy estimand

    An estimand defines the treatment effect a trial aims to estimate, including how treatment discontinuation or other events are handled. The analysis label above is reproduced from the verified record; methods should be checked in its source.

    Study-arm labels describe the research, not dosing advice. Efficacy does not establish safety, and cross-trial comparisons are not head-to-head comparisons.

    Figure source: Eli Lilly — TRANSCEND-T2D-1 topline results (19 Mar 2026)Published 19 Mar 2026 · Verified 30 Sept 2026

    Trial design and endpointsVerified safety evidence

Open the full Results Explorer (29 verified results) →

Literature

Latest Retatrutide Research

Peer-reviewed publications covering pharmacology, efficacy and safety of retatrutide.

View all research
OtherPMID 42745421

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.

Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, Pereira HMG

Rapid communications in mass spectrometry : RCM · Journal issue: 15 Dec 2026

Abstract excerpt

RATIONALE: Retatrutide (LY3437943) is a novel long-acting triple incretin receptor agonist that targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).

SummaryView Source
Clinical trial resultsPMID 42608321

Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.

Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ

Diabetes, obesity & metabolism · 1 Nov 2026

Abstract excerpt

AIMS: To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). MATERIALS AND METHODS: Data were analysed from two randomised, double-blind, placebo-controlled phase 2 trials.

SummaryView Source
OtherPMID 42603384

Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.

Tong LH, Leung KK, Hung CT

Journal of chromatography. A · 11 Oct 2026

SummaryView Source
Clinical trial resultsPMID 42810372

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A

Lancet (London, England) · 10 Oct 2026

Abstract excerpt

BACKGROUND: Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea. We aimed to assess the efficacy and safety of retatrutide in adults with obesity and type 2 diabetes.

SummaryView Source
OtherPMID 42849462

Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?

Holst JJ

Lancet (London, England) · 10 Oct 2026

SummaryView Source

Competitive Landscape

How Retatrutide Compares

Side-by-side reference notes on mechanism, development stage and reported efficacy across leading candidates.

Cross-trial comparisons should be interpreted cautiously because study populations, trial designs, treatment durations and endpoints may differ.

Retatrutide vs Tirzepatide

Full comparison
Developer
Eli Lilly and CompanyEli Lilly and Company
Mechanism
GLP-1 / GIP / Glucagon triple agonistGLP-1 / GIP dual agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous
Development Stage
Phase 3Approved (obesity, type 2 diabetes)
Studied Population
Obesity ± type 2 diabetesObesity, type 2 diabetes, OSA
Regulatory Status
InvestigationalApproved

Retatrutide vs Semaglutide

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistGLP-1 receptor agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous or oral
Development Stage
Phase 3Approved (obesity, type 2 diabetes)
Studied Population
Obesity ± type 2 diabetesObesity, type 2 diabetes, CV risk
Regulatory Status
InvestigationalApproved

Retatrutide vs CagriSema

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistAmylin analogue + GLP-1 agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous
Development Stage
Phase 3Phase 3 / regulatory submission
Studied Population
Obesity ± type 2 diabetesObesity, type 2 diabetes
Regulatory Status
InvestigationalInvestigational

Retatrutide vs Amycretin

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistAmylin + GLP-1 receptor co-agonist
Administration
Once-weekly subcutaneousSubcutaneous or oral (in development)
Development Stage
Phase 3Phase 2
Studied Population
Obesity ± type 2 diabetesOverweight and obesity
Regulatory Status
InvestigationalInvestigational

Retatrutide vs MariTide

Full comparison
Developer
Eli Lilly and CompanyAmgen
Mechanism
GLP-1 / GIP / Glucagon triple agonistGIP receptor antagonist / GLP-1 agonist
Administration
Once-weekly subcutaneousMonthly or less frequent subcutaneous
Development Stage
Phase 3Phase 3
Studied Population
Obesity ± type 2 diabetesObesity, type 2 diabetes
Regulatory Status
InvestigationalInvestigational
View all comparisons →

Pipeline

Next-Generation Obesity Drug Pipeline

The competitive set of incretin, amylin and multi-receptor candidates in late-stage obesity development.

DrugDeveloperMechanismAdministrationPhasePrimary Indication
Retatrutide (LY3437943)Eli Lilly and CompanyGLP-1 / GIP / GlucagonWeekly subcutaneousPhase 3Obesity
CagriSemaNovo NordiskAmylin + GLP-1Weekly subcutaneousPhase 3Obesity
OrforglipronEli Lilly and CompanyOral GLP-1 (non-peptide)Daily oralPhase 3Obesity, type 2 diabetes
MariTideAmgenGIP antagonist / GLP-1 agonistMonthly subcutaneousPhase 3Obesity
AmycretinNovo NordiskAmylin + GLP-1Subcutaneous / oralPhase 2Obesity
SurvodutideBoehringer Ingelheim / ZealandGLP-1 / GlucagonWeekly subcutaneousPhase 3Obesity, MASH
PetrelintideZealand Pharma / RocheAmylin analogueWeekly subcutaneousPhase 2Obesity
View full pipeline →